{
    "organizations": [],
    "uuid": "733460325a4cf12c90cd2fbeb1bd85b080a5b36c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-morphotek-announces-fda-acceptance/brief-morphotek-announces-fda-acceptance-of-ind-for-cancer-treatment-idUSASB0C0JO",
    "ord_in_thread": 0,
    "title": "BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 10, 2018 / 2:35 PM / Updated 28 minutes ago BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment Reuters Staff \nJan 10 (Reuters) - Eisai Co Ltd: \n* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202 \n* MORPHOTEK - U.S. FDA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION FOR MORAB-202 Source text for Eikon: Further company coverage:",
    "published": "2018-01-10T16:35:00.000+02:00",
    "crawled": "2018-01-10T16:56:02.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "fda",
        "acceptance",
        "ind",
        "cancer",
        "treatment",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "eisai",
        "co",
        "ltd",
        "morphotek",
        "announces",
        "fda",
        "acceptance",
        "investigational",
        "new",
        "drug",
        "application",
        "farletuzumab",
        "conjugate",
        "morphotek",
        "fda",
        "accepted",
        "investigational",
        "new",
        "drug",
        "application",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}